Investigative and emerging treatments for Batten disease

Bibliography

• Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta 2013;1832:1795-800
   PubMed Web of Science ®Google Scholar
• Warrier V, Vieira M, Mole SE. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta 2013;1832:1827-30
   PubMed Web of Science ®Google Scholar
• Kyttala A, Lahtinen U, Braulke T, Hofmann SL. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim Biophys Acta 2006;1762:920-33
   PubMed Web of Science ®Google Scholar
• Kollmann K, Uusi-Rauva K, Scifo E, et al. Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochim Biophys Acta 2013;1832:1866-81
   PubMed Web of Science ®Google Scholar
• Palmer DN, Barry LA, Tyynela J, Cooper JD. NCL disease mechanisms. Biochim Biophys Acta 2013;1832:1882-93
   PubMed Web of Science ®Google Scholar
• Schulz A, Kohlschutter A, Mink J, et al. NCL diseases - clinical perspectives. Biochim Biophys Acta 2013;1832:1801-6
   PubMed Web of Science ®Google Scholar
• Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol 2013;28:1142-50
   PubMed Web of Science ®Google Scholar
• Cárcel-Trullols J, Kovács AD, Pearce DA. Cell biology of the NCL proteins: What they do and don’t do. Biochim Biophys Acta 2015;10.1016/j.bbadis.2015.04.027
   PubMedGoogle Scholar
• Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162:570-2
   PubMed Web of Science ®Google Scholar
• Neufeld EF. Enzyme replacement therapy - a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford University Press, Oxford; 2006
   Google Scholar
• Wong AM, Rahim AA, Waddington SN, Cooper JD. Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis. Biochem Soc Trans 2010;38:1484-8
   PubMed Web of Science ®Google Scholar
• Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004;27:385-410
   PubMed Web of Science ®Google Scholar
• Lu JY, Hu J, Hofmann SL. Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2010;99:374-8
   PubMed Web of Science ®Google Scholar
• Hu J, Lu JY, Wong AM, et al. Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2012;107:213-21
   PubMed Web of Science ®Google Scholar
• Lin L, Lobel P. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. Biochem J 2001;357:49-55
   PubMed Web of Science ®Google Scholar
• Golabek AA, Wujek P, Walus M, et al. Maturation of human tripeptidyl-peptidase I in vitro. J Biol Chem 2004;279:31058-67
   PubMed Web of Science ®Google Scholar
• Vuillemenot BR, Kennedy D, Reed RP, et al. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution. Toxicol Appl Pharmacol 2014;277:49-57
   PubMed Web of Science ®Google Scholar
• Chang M, Cooper JD, Sleat DE, et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther 2008;16:649-56
   PubMed Web of Science ®Google Scholar
• Meng Y, Sohar I, Wang L, et al. Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification. PLoS One 2012;7:e40509
   PubMed Web of Science ®Google Scholar
• Meng Y, Sohar I, Sleat DE, et al. Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. Mol Ther 2014;22:547-53
   PubMed Web of Science ®Google Scholar
• Awano T, Katz ML, O’Brien DP, et al. A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis. Mol Genet Metab 2006;89:254-60
   PubMed Web of Science ®Google Scholar
• Vuillemenot BR, Katz ML, Coates JR, et al. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2011;104:325-37
   PubMed Web of Science ®Google Scholar
• Vuillemenot BR, Kennedy D, Cooper JD, et al. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Mol Genet Metab 2015;114:281-93
   PubMed Web of Science ®Google Scholar
• Katz ML, Coates JR, Sibigtroth CM, et al. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J Neurosci Res 2014;92:1591-8
   PubMed Web of Science ®Google Scholar
• Barranger JM, Novelli EA. Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2001;1:857-67
   PubMed Web of Science ®Google Scholar
• Poenaru L. From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system. Ann Med 2001;33:28-36
   PubMed Web of Science ®Google Scholar
• Cabrera-Salazar MA, Novelli E, Barranger JA. Gene therapy for the lysosomal storage disorders. Curr Opin Mol Ther 2002;4:349-58
   PubMed Web of Science ®Google Scholar
• Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006;13:839-49
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Hackett PB. Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier. Mol Genet Metab 2015;114:83-93
   PubMed Web of Science ®Google Scholar
• Sondhi D, Hackett NR, Apblett RL, et al. Feasibility of Gene therapy for late neuronal ceroid lipofuscinosis. Arch Neurol 2001;58:1793-8
   PubMed Web of Science ®Google Scholar
• Hobert JA, Dawson G. Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future. Biochim Biophys Acta 2006;1762:945-53
   PubMed Web of Science ®Google Scholar
• Hawkins-Salsbury JA, Cooper JD, Sands MS. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease). Biochim Biophys Acta 2013;1832:1906-9
   PubMed Web of Science ®Google Scholar
• Sleat DE, El-Banna M, Sohar I, et al. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis. Mol Genet Metab 2008;94:222-33
   PubMed Web of Science ®Google Scholar
• Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11
   PubMed Web of Science ®Google Scholar
• Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006;14:316-27
   PubMed Web of Science ®Google Scholar
• Rahim AA, Wong AM, Howe SJ, et al. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther 2009;16:509-20
   PubMed Web of Science ®Google Scholar
• Rahim AA, Wong AM, Ahmadi S, et al. In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression. Gene Ther 2012;19:936-46
   PubMed Web of Science ®Google Scholar
• Rahim AA, Wong AM, Hoefer K, et al. Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J 2011;25:3505-18
   PubMed Web of Science ®Google Scholar
• Ghodsi A, Stein C, Derksen T, et al. Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum Gene Ther 1998;9:2331-40
   PubMed Web of Science ®Google Scholar
• Griffey M, Bible E, Vogler C, et al. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 2004;16:360-9
   PubMed Web of Science ®Google Scholar
• Lin D, Fantz CR, Levy B, et al. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther 2005;12:422-30
   PubMed Web of Science ®Google Scholar
• Watson G, Bastacky J, Belichenko P, et al. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther 2006;13:917-25
   PubMed Web of Science ®Google Scholar
• Liu G, Martins I, Wemmie JA, et al. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 2005;25:9321-7
   PubMed Web of Science ®Google Scholar
• Chen YH, Chang M, Davidson BL. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 2009;15:1215-18
   PubMed Web of Science ®Google Scholar
• Griffey MA, Wozniak D, Wong M, et al. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther 2006;13:538-47
   PubMed Web of Science ®Google Scholar
• Griffey MA, Macauley SL, Ogilvie JM, Sands MS. CNS-directed AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther 2005;12:413-21
   PubMed Web of Science ®Google Scholar
• Macauley SL, Roberts MS, Wong AM, et al. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann Neurol 2012;71:797-804
   PubMed Web of Science ®Google Scholar
• Haskell RE, Hughes SM, Chiorini JA, et al. Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Ther 2003;10:34-42
   PubMed Web of Science ®Google Scholar
• Sondhi D, Peterson DA, Giannaris EL, et al. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther 2005;12:1618-32
   PubMed Web of Science ®Google Scholar
• Passini MA, Dodge JC, Bu J, et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci 2006;26:1334-42
   PubMed Web of Science ®Google Scholar
• Sondhi D, Hackett NR, Peterson DA, et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007;15:481-91
   PubMed Web of Science ®Google Scholar
• Sondhi D, Peterson DA, Edelstein AM, et al. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp Neurol 2008;213:18-27
   PubMed Web of Science ®Google Scholar
• Sondhi D, Johnson L, Purpura K, et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods 2012;23:324-35
   PubMed Web of Science ®Google Scholar
• Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19:463-74
   PubMed Web of Science ®Google Scholar
• Shihabuddin LS, Cheng SH. Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases. Neurotherapeutics 2011;8:659-67
   PubMed Web of Science ®Google Scholar
• Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br J Haematol 2010;148:356-72
   PubMed Web of Science ®Google Scholar
• Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 2000;97:10954-9
   PubMed Web of Science ®Google Scholar
• Cooper JD. The neuronal ceroid lipofuscinoses: the same, but different? Biochem Soc Trans 2010;38:1448-52
   PubMed Web of Science ®Google Scholar
• Lonnqvist T, Vanhanen SL, Vettenranta K, et al. Hematopoietic stem cell transplantation in infantile neuronal ceroid lipofuscinosis. Neurology 2001;57:1411-16
   PubMed Web of Science ®Google Scholar
• Yuza Y, Yokoi K, Sakurai K, et al. Allogenic bone marrow transplantation for late-infantile neuronal ceroid lipofuscinosis. Pediatr Int 2005;47:681-3
   PubMed Web of Science ®Google Scholar
• Tamaki SJ, Jacobs Y, Dohse M, et al. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell 2009;5:310-19
   PubMed Web of Science ®Google Scholar
• Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr 2013;11:643-52
   PubMed Web of Science ®Google Scholar
• Zhang Z, Butler JD, Levin SW, et al. Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood. Nat Med 2001;7:478-84
   PubMed Web of Science ®Google Scholar
• Levin SW, Baker EH, Zein WM, et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol 2014;13:777-87
   PubMed Web of Science ®Google Scholar
• Roberts MS, Macauley SL, Wong AM, et al. Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis 2012;35:847-57
   PubMed Web of Science ®Google Scholar
• Wei H, Zhang Z, Saha A, et al. Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol. Hum Mol Genet 2011;20:1111-21
   PubMed Web of Science ®Google Scholar
• Das AK, Becerra CH, Yi W, et al. Molecular genetics of palmitoyl-protein thioesterase deficiency in the U.S. J Clin Invest 1998;102:361-70
   PubMed Web of Science ®Google Scholar
• Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91
   PubMed Web of Science ®Google Scholar
• Sarkar C, Zhang Z, Mukherjee AB. Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol Genet Metab 2011;104:338-45
   PubMed Web of Science ®Google Scholar
• Miller JN, Kovacs AD, Pearce DA. The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy. Hum Mol Genet 2015;24:185-96
   PubMed Web of Science ®Google Scholar
• Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010;285:20423-7
   PubMed Web of Science ®Google Scholar
• Macauley SL, Wong AM, Shyng C, et al. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci 2014;34:13077-82
   PubMed Web of Science ®Google Scholar
• Hu W, Ralay Ranaivo H, Roy SM, et al. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett 2007;17:414-18
   PubMed Web of Science ®Google Scholar
• Bachstetter AD, Norris CM, Sompol P, et al. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer’s disease-related pathology. J Neurosci 2012;32:10201-10
   PubMed Web of Science ®Google Scholar
• Siintola E, Lehesjoki AE, Mole SE. Molecular genetics of the NCLs – status and perspectives. Biochim Biophys Acta 2006;1762:857-64
   PubMed Web of Science ®Google Scholar
• Pontikis CC, Cella CV, Parihar N, et al. Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res 2004;1023:231-42
   PubMed Web of Science ®Google Scholar
• Pontikis CC, Cotman SL, Macdonald ME, Cooper JD. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. Neurobiol Dis 2005;20:823-36
   PubMed Web of Science ®Google Scholar
• Weimer JM, Custer AW, Benedict JW, et al. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol Dis 2006;22:284-93
   PubMed Web of Science ®Google Scholar
• Weimer JM, Benedict JW, Getty AL, et al. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res 2009;1266:93-107
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Ito M, Cooper JD, et al. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum Mol Genet 2002a;1421-31
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Kriscenski-Perry E, Wenger DA, Pearce DA. An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses. Neurology 2002b;59:1816-17
   PubMed Web of Science ®Google Scholar
• Lim MJ, Beake J, Bible E, et al. Distinct patterns of serum immunoreactivity as evidence for multiple brain-directed autoantibodies in juvenile neuronal ceroid lipofuscinosis. Neuropathol Appl Neurobiol 2006;32:469-82
   PubMed Web of Science ®Google Scholar
• Lim MJ, Alexander N, Benedict JW, et al. IgG entry and deposition are components of the neuroimmune response in Batten disease. Neurobiol Dis 2007;25:239-51
   PubMed Web of Science ®Google Scholar
• Castaneda JA, Pearce DA. Identification of alpha-fetoprotein as an autoantigen in juvenile Batten disease. Neurobiol Dis 2008;29:92-102
   PubMed Web of Science ®Google Scholar
• Pears MR, Cooper JD, Mitchison HM, et al. High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem 2005;280:42508-14
   PubMed Web of Science ®Google Scholar
• Kovacs AD, Weimer JM, Pearce DA. Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. Neurobiol Dis 2006;22:575-85
   PubMed Web of Science ®Google Scholar
• Kovacs AD, Pearce DA. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp Neurol 2008;209:288-91
   PubMed Web of Science ®Google Scholar
• Kovacs AD, Saje A, Wong A, et al. Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease. Neuropharmacology 2011;60:405-9
   PubMed Web of Science ®Google Scholar
• Kovacs AD, Saje A, Wong A, et al. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Neuropharmacology 2012;63:769-75
   PubMed Web of Science ®Google Scholar
• Seehafer SS, Ramirez-Montealegre D, Wong AM, et al. Immunosuppression alters disease severity in juvenile Batten disease mice. J Neuroimmunol 2011;230:169-72
   PubMed Web of Science ®Google Scholar
• Xiong J, Kielian T. Microglia in juvenile neuronal ceroid lipofuscinosis are primed toward a pro-inflammatory phenotype. J Neurochem 2013;127:245-58
   PubMed Web of Science ®Google Scholar
• Burkovetskaya M, Karpuk N, Xiong J, et al. Evidence for aberrant astrocyte hemichannel activity in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL). PLoS One 2014;9:e95023
   PubMed Web of Science ®Google Scholar
• Sharp JD, Wheeler RB, Lake BD, et al. Genetic and physical mapping of the CLN6 gene on chromosome 15q21-23. Mol Genet Metab 1999;66:329-31
   PubMed Web of Science ®Google Scholar
• Gao H, Boustany RM, Espinola JA, et al. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet 2002;70:324-35
   PubMed Web of Science ®Google Scholar
• Heine C, Koch B, Storch S, et al. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J Biol Chem 2004;279:22347-52
   PubMed Web of Science ®Google Scholar
• Mole SE, Michaux G, Codlin S, et al. CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp Cell Res 2004;298:399-406
   PubMed Web of Science ®Google Scholar
• Mirza M, Volz C, Karlstetter M, et al. Progressive retinal degeneration and glial activation in the CLN6 (nclf) mouse model of neuronal ceroid lipofuscinosis: a beneficial effect of DHA and curcumin supplementation. PLoS ONE 2013;8:e75963
   PubMed Web of Science ®Google Scholar
• Sondhi D, Scott EC, Chen A, et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Hum Gene Ther 2014;25:223-39
   PubMed Web of Science ®Google Scholar
• O’hare MB, Tear G. Interactions between the juvenile Batten disease gene, CLN3, and the Notch and JNK signalling pathways. Hum Mol Genet 2009;18:667-78
   PubMed Web of Science ®Google Scholar
• Tomiyasu H, Takahashi W, Ohta T, et al. [An autopsy case of juvenile neuronal ceroid-lipofuscinosis with dilated cardiomyopathy]. Rinsho Shinkeigaku 2000;40:350-7
   PubMedGoogle Scholar
• Hofman IL, van der Wal AC, Dingemans KP, Becker AE. Cardiac pathology in neuronal ceroid lipofuscinoses–a clinicopathologic correlation in three patients. Eur J Paediatr Neurol 2001;5(Suppl A):213-17
   PubMedGoogle Scholar
• Ostergaard JR, Rasmussen TB, Molgaard H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 2011;76:1245-51
   PubMed Web of Science ®Google Scholar
• Fukumura S, Saito Y, Saito T, et al. Progressive conduction defects and cardiac death in late infantile neuronal ceroid lipofuscinosis. Dev Med Child Neurol 2012;54:663-6
   PubMed Web of Science ®Google Scholar
• Marshall FJ, de Blieck EA, Mink JW, et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology 2005;65:275-9
   PubMed Web of Science ®Google Scholar
• Steinfeld R, Heim P, von Gregory H, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 2002;112:347-54
   PubMed Web of Science ®Google Scholar